清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.

医学 依西美坦 帕博西利布 卡培他滨 转移性乳腺癌 肿瘤科 兴奋剂 乳腺癌 内科学 三苯氧胺 妇科 癌症 受体 结直肠癌
作者
Yeon Hee Park,Kyung-Hun Lee,Gun Min Kim,Seok Yun Kang,Keun Seok Lee,Jee Hyun Kim,Kyoung Eun Lee,Hee Kyung Ahn,Moon Hee Lee,Hee Jun Kim,Hanjo Kim,Su‐Jin Koh,Ji‐Yeon Kim,Joohyuk Sohn,Sung‐Bae Kim,Jin Seok Ahn,Seonwoo Kim,Hyun Cho,Kyung Hae Jung,Seock‐Ah Im
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (17_suppl): LBA1002-LBA1002
标识
DOI:10.1200/jco.2024.42.17_suppl.lba1002
摘要

LBA1002 Background: The Young-PEARL study demonstrated improved progression free survival (PFS) (mPFS: 20.1 vs. 14.4 mo.) of exemestane plus palbociclib with ovarian function suppression (OFS) compared to capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer (mBC). Here we report updated survival outcomes with median follow-up of 54.8 months (data cutoff, November 30, 2023). Methods: Premenopausal women aged 19 years or older with HR+/HER2- BC who had relapsed or progressed during previous tamoxifen therapy were enrolled. One line of previous chemotherapy for mBC was allowed. The primary endpoint was PFS, which was defined as the time from C1D1 to disease progression or death. The key secondary endpoint was overall survival (OS). Other secondary endpoints included objective response rate (ORR) and toxicities. Results: 184 patients were randomly assigned to exemestane plus palbociclib with OFS (n=92) or capecitabine (n=92). Median age was 44.0 years (range, 28-58). Key efficacy and safety are shown in Table. Final analysis was conducted for 174 patients. The updated mPFS was 19.5 mo. (90% CI, 14.3-22.3) for exemestane + palbociclib + OFS compared with 14.0 mo. (90% CI, 11.7-18.7) for capecitabine (HR 0.75, P=0.04). mOS was 54.8 mo. (95% CI, 48.9-77.1) for palbociclib arm and 57.8 mo. (95% CI, 46.3-N/A) for capecitabine arm (HR 1.06, P=0.77). mPFS2 (from the date of 1 st PD to 2 nd PD) was significantly shorter in palbociclib arm than those of capecitabine arm (7.5 vs. 11.7 mo. P=0.02). Confirmed ORR based on the investigator assessments was 33.3% (95% CI, 23.6-43.1) for palbociclib and 33.7% (95% CI, 23.6-43.9) for capecitabine. Median treatment duration was 18.9 mo. (range 1.6-88.4) in palbociclib and 13.5 mo. (range 0.1-70.8) in capecitabine. In palbociclib arm, 86 (93.5%) experienced grade 3 or more TEAEs, mainly asymptomatic neutropenia (64.1%), compared to 41 (48.2%) patients with grade ≥3 TEAEs in the capecitabine arm, mainly Hand-Foot syndrome and neutropenia (18.8% for each). Conclusions: Young-PEARL study showed exemestane + palbociclib with OFS improves efficacy compared with capecitabine in terms of PFS, which did not lead to an OS benefit for patients with premenopausal HR+/HER2- mBC (median follow-up duration: 54.8 months). The overall safety profile of palbociclib and capecitabine continues to be manageable with longer follow-up. Clinical trial information: NCT02592746 . [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
喜悦半莲完成签到,获得积分10
9秒前
psm完成签到 ,获得积分10
11秒前
33秒前
失眠的修杰完成签到,获得积分10
39秒前
42秒前
acat完成签到 ,获得积分10
42秒前
超级无敌万能小金毛完成签到,获得积分10
42秒前
45秒前
单薄涵梅完成签到,获得积分10
1分钟前
老戎完成签到 ,获得积分10
1分钟前
爱笑的笑旋完成签到,获得积分10
1分钟前
爆米花的应助被科研通管家采纳,获得10
1分钟前
nnn关闭了nnn的文献求助
1分钟前
科研民工完成签到,获得积分10
1分钟前
Zyou完成签到,获得积分10
1分钟前
落后的雨筠完成签到,获得积分10
1分钟前
1分钟前
大意的之柔完成签到,获得积分10
2分钟前
依然灬聆听完成签到,获得积分10
2分钟前
会发光的小叶子完成签到,获得积分10
2分钟前
漂亮傲云完成签到,获得积分10
2分钟前
勤劳寒松完成签到,获得积分10
2分钟前
风趣馒头完成签到,获得积分10
2分钟前
激动的发卡完成签到,获得积分10
2分钟前
李健的应助被科研通管家采纳,获得10
3分钟前
Maestro_S的应助被科研通管家采纳,获得10
3分钟前
null的应助被科研通管家采纳,获得10
3分钟前
时尚的青易完成签到,获得积分10
3分钟前
感性的鸡完成签到,获得积分10
3分钟前
嘻嘻完成签到,获得积分10
4分钟前
英俊的青烟完成签到,获得积分10
4分钟前
marine完成签到 ,获得积分10
4分钟前
4分钟前
向连虎发布了新的文献求助10
4分钟前
4分钟前
超级诗桃完成签到,获得积分10
4分钟前
绛仙旧友完成签到,获得积分10
4分钟前
无辜的水蜜桃完成签到,获得积分10
5分钟前
liunahan完成签到 ,获得积分10
5分钟前
JUN完成签到,获得积分10
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166338
求助须知:如何正确求助?哪些是违规求助? 9559484
关于积分的说明 21750435
捐赠科研通 7757131
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553469
邀请新用户注册赠送积分活动 2473812